Fig. 5.

Targeting of certain cancers with 12 epi-drugs, including examples of clinical trial. The graph depicts the clinical trials of these PRMT, EZH2, LSD1, HDAC and DNMT inhibitors based on searches of the ClinicalTrials.gov database (https://clinicaltrials.gov/). Epi-drugs play an active role in hematological and solid tumors. However, epi-drugs that are mainly EZH2 inhibitors and PRMT inhibitors are more widely used in hematological tumors than in solid tumors. Moreover, the efficacy of EZH2 inhibitors and PRMT inhibitors in solid tumors is still limited. The effects of LSD1 inhibitors, HDAC inhibitors, and DNMT inhibitors on hematological tumors have also been analyzed in several clinical trials. However, clinical studies on their role in solid tumors such as lung cancer, breast cancer, and renal cancer have currently been successively carried out